First introduced by Mainz Biomed in mid-2024, the enhanced ColoAlert features state-of-the-art advancements, including a proprietary DNA stabilizing buffer, to deliver accurate results even with ...

Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...

The study objective is to provide current estimates of utilization/spending trends for molecular diagnostic and genetic testing for commercially insured, Medicare and Medicaid populations.

This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to electronically order and track Prolaris and MyRisk tests, with results delivered ...

Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer ...

PRNewswireNew York [US]/ London [UK]/ Munich [Germany]/ New Delhi [India], February 11: Datar Cancer Genetics (DCG), a global ...

(RTTNews) - Mainz Biomed N.V. (MYNZ), a molecular genetics diagnostic company, announced on Monday, that it has regained compliance with Nasdaq's continued listing requirements. The company ...

Continued innovation and investment in molecular diagnostics will ensure broader access and better preparedness for HMPV, its variants and other respiratory illnesses.

and MAINZ, Germany, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early ...